source
- Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpointA pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the drugmaker’s efforts to challenge Johnson & Johnson for the post-BCMA multip…Fierce Biotech · 5h ago↗ source
- Boston Scientific recalls spinal cord implant in wake of more than 1k serious injuriesBoston Scientific has issued another recall, this time for its spinal cord implant used to treat pain.Fierce Biotech · 6h ago↗ source
- Novo Nordisk abandons two phase 3 trials of ziltivekimab, dimming blockbuster hopesNovo Nordisk announced it is terminating two late‑stage phase 3 studies of its IL‑6 ligand antibody ziltivekimab. The Hermes and Athena trials enrolled about 4,900 and 673 patients with heart fail…